RepSox

Research use only, not for human use.

RepSox (E-616452, SJN-2511) is a potent, selective inhibitor of TGF-β type I receptor ALK5 with Ki of 25 nM.

RepSox (E-616452, SJN-2511) is a potent, selective inhibitor of TGF-β type I receptor ALK5 with Ki of 25 nM, inhibits ALK5 autophosphorylation with IC50 of 4 nM, can replace the central reprogramming factor Sox2 by inducing nanog; specifically acts by inhibiting Tgf-β signaling, does not act by inducing Sox2 expression in the target fibroblasts; efficiently replaces transgenic Sox2 in the absence of VPA and c-Myc, as well as in both embryonic and adult fibroblasts; demonstrates effectivity at generating iPSCs.

RepSox (GMP) (10 μM) induces MEFs differentiating to chemically induced pluripotent stem cells (CiPSCs).RepSox (GMP) (10 μM, in stage I-Stage III induction medium) induces hCiPS cells from HEFs.RepSox (GMP) together with Forskolin (HY-15371) increases the number of proliferative cells in MEFs expressing MyoD, confirmed by increased EdU incorporation.

——

E-616452 | SJN 2511 | E616452 | SJN2511 | E 616452 | SJN-2511

TGF-beta/Smad

TGFBR

ALK5|TGFβR1

Cancer

——

446859-33-2

287.3186

C17H13N5

>98% (HPLC)

DMSO: ≥ 52 mg/mL

CC1=CC=CC(C2=NNC=C2C3=NC4=CC=CN=C4C=C3)=N1

2-(3-(6-methylpyridin-2-yl)-1H-pyrazol-4-yl)-1,5-naphthyridine

(-20℃)

With Ice Pack

≥ 2 years